Plasma-glycated CD59 as an early biomarker for gestational diabetes mellitus: prospective cohort study protocol.

ABSTRACT:

Introduction

The significant maternal and neonatal outcomes of gestational diabetes mellitus (GDM) make it a major public health concern. Mothers with GDM are at greater risk of pregnancy complications and their offspring are at higher risk of diabetes and obesity. Currently, GDM is diagnosed with glucose load methods which are time-consuming and inconvenient to administer more than once during pregnancy; for this reason, there is a recognised need for a more accurate and simpler test for GDM. Previous studies indicate that plasma-glycated CD59 (pGCD59) is a novel biomarker for GDM. We present here the protocol of a prospective cohort study designed to (1) determine the accuracy of pGCD59 as an early, first trimester predictor of GDM and gestational impaired glucose tolerance and (

SUBMITTER: Andrews C 

PROVIDER: S-EPMC9021770 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature